New hope for Tough-to-Treat breast cancer: testing a drug after standard chemo fails
NCT ID NCT04489173
Summary
This study is testing whether the drug trifluridine/tipiracil can help control advanced breast cancer that has stopped responding to standard chemotherapy. It is for women with a specific type (ER-positive, HER2-negative) who have already been treated with two common chemo drugs. The main goal is to see if the drug can keep the cancer from growing for at least 8 weeks and to monitor side effects and quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Amphia Ziekenhuis
Breda, Netherlands
-
Catharina Ziekenhuis
Eindhoven, Netherlands
-
Deventer ziekenhuis
Deventer, Netherlands
-
Erasmus MC
Rotterdam, Netherlands
-
MC Leeuwarden
Leeuwarden, Netherlands
-
MUMC
Maastricht, Netherlands
-
Reinier de Graaf Groep
Delft, Netherlands
-
Rijnstate
Arnhem, Netherlands
-
UMC Utrecht
Utrecht, Netherlands
-
Wilhelmina ziekenhuis
Assen, Netherlands
Conditions
Explore the condition pages connected to this study.